XT-150 is under clinical development by Xalud Therapeutics and currently in Phase II for Peripheral Neuropathic Pain. According to GlobalData, Phase II drugs for Peripheral Neuropathic Pain have a 19% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how XT-150’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

XT-150 overview

XT-150 is under development for the treatment of peripheral neuropathic pain-lumbar radiculopathy, central neuropathic pain, multiple sclerosis, facet syndrome, osteoarthritis, osteoarthritis pain, amyotrophic lateral sclerosis, unspecified dermatological disorders and unspecified ophthalmological disorders. It is administered through the parenteral, intraarticular and intrathecal route. The drug candidate is a non-viral vector-based gene therapy that comprises of a combination of plasmid DNA nucleic acid expressing IL-10 protein and a compound that improves the uptake of the plasmid into cells. It was also under development for the treatment of chemotherapy-induced peripheral neuropathy, thermal analgesia, degenerative disc disease and unspecified gastrointestinal disorders.

Xalud Therapeutics overview

Xalud Therapeutics provides healthcare services. The company develops novel therapies for the treatment of neuro-inflammatory diseases such as neuropathic pain, multiple sclerosis, and amyotrophic lateral sclerosis. It is headquartered in San Francisco, California, United States.

For a complete picture of XT-150’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.